Patients with inflammatory gynecological/obstetrical problems often complain of irritable bowel syndrome. The authors examined whether acute uterus irritation reflexively provokes colonic motility in rat preparations.
A modified colon manometry and striated abdominal muscle electromyogram activity in response to mustard oil (MO) instillation into the uterine horn were continuously recorded in anesthetized rats. The lumbosacral (L6-S1) dorsal horn was dissected to assess the level and the cellular location of phosphorylated NR2B subunit using Western blotting and immunofluorescence analysis, respectively. Finally, the uterine transient receptor potential A1 or spinal NR2B subunit was pharmacologically blocked to elucidate its roles.
MO (0.1%, 0.2 ml) injected into the lower uterine horn dramatically provoked colonic hypermotility characterized by rhythmic colonic contractions (about 3–4 contractions per 10 min, n = 7) accompanied by synchronized electromyogram firing in the abdominal muscle (about 4–5 folds of control, n = 7). In addition to provoking colonic hypermotility, MO administration also up-regulated phosphorylated (about 2–3 folds of control, n = 7), but not total, NR2B expression in the dorsal horn neurons. Both intrathecal Ro 25–6981 (a selective NR2B subunit antagonist; 10 μM, 10 μl) and intrauterine HC-030031 (a selective transient receptor potential A1 receptor antagonist; 30 mg/kg, 0.2 ml) injected before the MO instillation attenuated the MO-induced colonic hypermotility and spinal NR2B phosphorylation.
The comorbidity of gynecological/obstetrical and gastrointestinal problems is not coincidental but rather causal in nature, and clinicians should investigate for gynecological/urological diseases in the setting of bowel problems with no known pathological etiology.
Cross-organ sensitization has been inferred from epidemiological data and has been studied in animals
In particular, there may be an association between pain- related gynecological problems and irritable bowel syndrome
Rats were used to show that irritation of the uterus with mustard oil provoked colonic hypermotilty
These effects were shown to be dependent on local transient receptor potential subfamily ankyrin 1 channel activation and spinal NR2B receptor stimulation
ACUTE irritation of pelvic organs was shown to provoke phosphorylation of the NR2B subunit of glutamatergic N-methyl-d-aspartate receptors (NMDARs) in the lumbosacral dorsal horn.1–4 Both focal knockdown of spinal NR2B expression3 and spinal administration of reagents selectively antagonizing NR2B phosphorylation1–3 thwarted the irritation-induced visceral hyperreflexia, suggesting that spinal NR2B phosphorylation plays a crucial role in visceral pain pathology.
Although the underlying mechanism remains unclear, epidemiological studies demonstrate patients with inflammatory pain-associated gynecological problems, such as endometriosis or dysmenorrhea, often complain of irritable bowel syndrome (IBS).5–7 Cross-organ sensitization, a phenomenon in which inflammation/injury enhances the NMDAR-mediated neurotransmission both in the dorsal horn of the damaged viscera itself and in unaffected neighboring organs, has recently emerged as an important theme in researches investigating the concurrence of problems in pelvic viscera.8–10 Our laboratory demonstrated that acute uterus irritation dynamically enhances pain-related urethra electromyogram activity via spinal NR2B phosphorylation.1,11 Nevertheless, whether damages in the uterus could also reflexively affect bowel functions, demonstrating the comorbidity of gynecological problems and IBS, and the possible role of spinal NR2B subunit has not yet been clearly investigated.
Although there is sparse direct immunohistochemical evidence demonstrated the transient receptor potential subfamily ankyrin 1 (TRPA1)12 –expressing afferents innervate the pelvic viscera,13 pharmacological activation of TRPA1 modifies the function of the urinary bladder,14 urethra,15 colon,16,17 and uterus.10 This suggests a role of TRPA1 in the neural regulation of lower urogenital and gastrointestinal tracts. Knockout of mouse TRPA1 prevents the enhanced visceromotor response caused by 2,4,6-trinitrobenzene sulfonic acid–induced colitis and colon irritation induced by acute mustard oil (MO; a selective TRPA1 agonist) instillation.18 Moreover, TRPA1 activation caused by a brief intracolonic MO application increased spontaneous excitatory postsynaptic potentials in a spinal slice through the selective potentiation of glutamate-mediated neurotransmission in the substantia gelatinosa, a key site for noxious input integration.19 Interestingly, studies in which MO was applied into the descending colon have demonstrated the MO-induced spinal NR2B phosphorylation is an important determinant for the cross-organ sensitization among pelvic viscera.3,4,20,21 These studies prompt us to investigate whether and how the activation of nociceptive TRPA1-expressing afferents and the subsequent spinal NR2B phosphorylation participate in uterus–colon crosstalk, a possible mechanism underlying the concurrence of gynecological pain and IBS.
We hypothesized that acute uterus irritation provokes colonic hypermotility via the spinal NR2B phosphorylation. Thereby, we recorded colon motility and analyzed the spinal expression and location of phosphorylated NR2B in response to intrauterine MO instillation. Moreover, uterine TRPA1 and spinal NR2B were pharmacologically antagonized to elucidate their roles in the uterus–colon crosstalk.
Materials and Methods
All procedures for animal studies were reviewed and approved by the Institutional Review Board of National Chung-Hsing University, Taichung, Taiwan. Two hundred sixty-three female Sprague–Dawley rats, weighing 250–300 g, were randomly assigned to groups and used throughout this study. Animals were individually housed in wood chip–lined plastic cages, had free access to water and food, and were maintained on a 12:12-h light–dark cycle with lights on at 07:00 am. The estrous stage was assessed daily at 9:00 am by vaginal lavage, using the traditional stage nomenclature.22 Rats that had two complete, regular 4-day estrous cycles before the day of the experiment were used for this study. Measurements were made approximately 5–8 h after the lights were turned on and when the rats were in the diestrus stage (when both estradiol and progesterone are low).22
In order to quickly achieve adequate anesthesia for surgical procedures, animals were first anesthetized with isoflurane (5% for induction and 2% for surgery). A PE-50 catheter (Portex, Hythe, Kent, United Kingdom) was placed in the left jugular vein for anesthetic administration. A midline abdominal incision was made to expose the pelvic viscera. Two wide-bore uterine cannulae, one for drug injections and the other for fluid drainage, were inserted into the lumen of the right lower uterine horn through small incisions made on the uterine horn and secured with cotton thread. After all surgical procedures were completed, urethane (1.2 g/kg; Sigma-Aldrich, St. Louis, MO) was injected intravenously to maintain anesthesia, as this reagent produces a long duration of anesthesia after single bolus while causing minimal changes in the visceral and reflex response.23
Colonic Motility Recording
The motility of the descending colon was continuously recorded as changes in intracolonic pressure (ICP) using an approach modified from the studies by Gourcerol et al.24 and Carini et al.25 In brief, a catheter with a 4-cm deflated flexible latex balloon lubricated with medical-grade lubricant at the tip was inserted intraanally into the descending colon such that the end of the balloon was 1 cm proximal to the anus. The balloon was then filled with normal saline (approximately 0.5 ml) and the ICP was continuously recorded via a catheter connected to a pressure transducer (P23 ID; Gould-Statham, Quincy, IL) on a computer system (MP30; Biopac, Santa Barbara, CA) through a preamplifier (7P1; Grass, Cleveland, OH). Because our pilot experiments showed the maximal ICP provoked by the colonic irritation was approximately 30 mmHg (28.15 ± 3.21 mmHg), the motility of the descending colon was then quantified off-line by the number of contractions in which the amplitude was higher than 15 mmHg (about half the amplitude of the maximal contraction), using a program built in the recording software (Student Lab BSL PRO 3.7; Biopac; fig. 1A). Because balloon distension initially provoked rhythmic colonic contractions (RCCs) that gradually subsided, drug pretreatments, including intrauterine HC-030031 (a selective TRPA1 antagonist) or intrathecal Ro 25–6981 (a NMDAR NR2B subunit selective antagonist) were injected after a equilibrium period of 90 min after balloon distension. In all the cases (including animals that received no pretreated reagents), the ICP in response to intrauterine instillation of either MO or corn oil (CO) was continuously recorded for 60 min after a period of pretreatment (30 min). Therefore, the experiment usually finished 180 min after the starting of balloon distension.
In some experiments, electromyogram activity was picked up by Teflon-coated stainless steel wire electrodes stitched into the external oblique musculature immediately superior to the inguinal ligament. The electromyogram signals were continuously recorded on a computer system (MP30; Biopac) through a preamplifier (P511AC; Grass) using a band-pass filter with a frequency range of 30–3,000 Hz. The electromyogram activity was quantified off-line by integrating the area under the rectified electromyogram signal using a program built in the recording software (Student Lab BSL PRO 3.7; Biopac; fig. 1B).
Implantation of an intrathecal cannula was performed as described in our previous study.4 Briefly, the occipital crest of the skull was exposed, and the atlanto-occipital membrane was incised at the midline with the tip of an 18-gauge needle. A PE-10 catheter was inserted through the slit and passed caudally to the L6-S1 level of the dorsal aspect of the arachnoid space. The volume of fluid within the cannula was kept constant at 10 μl in all experiments. A single, 10 μl volume of drug solution was administered, followed by a 10 μl flush of vehicle solution. At the end of the experiment, a laminectomy was performed to verify the location of the cannula tip. In 5 of 64 rats, the cannula tip deviated by more than 0.5 mm from the target structure, and the data from these five cases were excluded from the statistical analysis.
Drugs that were administered by intrauterine, intracolonic, intrathecal, or intravenous injections included the following: MO (allyl isothiocyanate; 0.05, 0.1, and 0.5% dissolved in 0.2 ml CO; intrauterine; Sigma-Aldrich), a pungent component causing acute colon inflammation;3 CO (0.2 ml; intrauterine; Sigma-Aldrich), a control solution for MO;3 HC-030031 (HC, 30 mg/kg, 0.2 ml; intrauterine; Sigma-Aldrich), a TRPA1 receptor antagonist;26 acetic acid (1, 3, and 10%, 0.2 ml; intracolonic; Sigma-Aldrich), an irritant inducing colonic motility;23 Ro 25–6981 (RO, 10 μM, 10 μl; intrathecal; Sigma-Aldrich), a selective NMDAR NR2B subunit antagonist;2 ghrelin (1, 3, and 10 μg/kg, 10 μl; intrathecal; Sigma-Aldrich), an agent causing rhythmic colonic motility;27 and Evans Blue (50 mg/kg; intravenous; Sigma-Aldrich), a dye to quantify plasma extravasation.28 In all cases, solvent solutions of volume identical to those of the tested agents served as vehicle controls.
The rats were deeply anesthetized, and the spinal cords were quickly obtained before (preinjection control) and 10, 30, or 60 min after intrauterine MO injections. The dorsal horn of the right lumbosacral spinal cord (L6-S1) was dissected for Western blot analysis using methods described previously.29 In brief, protein samples (20 μg) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (8 and 12%), transferred to a nitrocellulose membrane, blocked in 5% nonfat milk and probed with antibodies against β-actin (1:8,000; Santa Cruz, Santa Cruz, CA) total and phosphorylated NR2B (tNR2B and pNR2B, respectively, 1:1,000; Millipore, Billerica, MA). The blots were incubated with horseradish peroxidase–conjugated antibody (1:2,000) for 1 h at room temperature and visualized with an enhanced chemiluminescence solution (5 min) followed by film exposure (2 min). Densitometric analysis of the western blot membrane was performed with Science Lab 2003 (LAS-300; Fuji, Kanagawa, Japan).
Quantitation of Plasma Protein Extravasation
A subset of animals was prepared to evaluate the effect of intrauterine MO on plasma protein extravasation in the uterus and colon.28 Evans Blue (50 mg/kg; Sigma-Aldrich) was injected intravenously 30 min before the removal of tissue. At the end of the experiments, the animals were decapitated and exsanguinated. The uterus and the descending colon were removed, blotted on wet filter paper, weighed, and stored in formamide at room temperature for 72 h to extract Evans Blue from the tissue. The amount of extracted Evans Blue was quantified by measuring the optical density of the extracted dye at a wavelength of 620 nm with the use of a spectrophotometer, and the value was expressed as micrograms per gram of wet tissue weight.28 The concentration was estimated from a standard regression curve for Evans Blue concentrations ranging from 0.1 to 5 μg/ml.
The rats were deeply anesthetized and perfused with 100 ml of 0.01 m phosphate-buffered saline (pH 7.4), followed by 300 ml of 4% paraformaldehyde in 0.1 m phosphate buffer (pH 7.4). The right lumbosacral spinal cord (L6-S1) was then harvested, postfixed at 4°C for 4 h, and cryoprotected in 30% sucrose overnight. For double-labeling immunohistochemistry analyses, the spinal cord sections were incubated overnight at 4°C with a mixture of rabbit antiphosphorylated NR2B (1:200; Abcam, Cambridge, United Kingdom) and mouse monoclonal antineuronal nuclear antigen (NeuN; a neuronal marker, 1:1,000; Chemicon, Billerica, MA), mouse antiglial fibrillary acidic protein (a marker of astroglial cells, 1:500; Millipore), or mouse antiintegrin αM (OX-42; a marker of microglia, 1:400; Santa Cruz). The sections were then incubated with Alexa Flour 488 (1:1,500) and Alexa Flour 594 (1:1,500; Invitrogen, Carlsbad, CA) for 1 h at 37°C.
A total of 263 rats were used in this study, including 142 rats for manometry recording and 121 rats for Western blot (70 rats), immunohistochemistry (26 rats), and plasma protein extravasation (25 rats) analyses. The density of specific bands from Western blot analysis was measured using computer-assisted imaging analysis (LAS-300; Fuji) and normalized against corresponding loading control bands. The motility of the descending colon was quantified by counting the ICP contractions, and electromyogram activity was quantified by integrating the area under the rectified electromyogram signal using programs built in the recording software (Student Lab BSL PRO 3.7; Biopac). All data were analyzed using SigmaPlot (version 10.0; Systat Software, Inc., San Jose, CA), and are presented as the mean ± SD. For serial measurements over time, one-way ANOVA was used to assess changes in values, and a Tukey post hoc test was used to compare means for groups. In experiments evaluating the effect of administration of different reagents, paired, two-tailed Student t test was used to compare means for groups. In all cases, significance was assigned at a P value less than 0.05.
Baseline Colonic Motility
To test the validity of the modified balloon method, we added normal saline (approximately 0.5 ml) into the balloon, which had been intraanally inserted into the descending colon of urethane-anesthetized rats, and the ICP was then continuously recorded. In all 142 rats tested, balloon distension provoked RCCs characterized by periodic peaks in the ICP, which gradually subsided during an equilibrium period (typically 90 min; fig. 1C). After the equilibrium period, the ICP maintained a relatively constant level without significant RCCs in 135 of 142 rats, and these animals were then used for further study. The manometric tracing in figure 1D demonstrated a stable ICP throughout the recording period, and summarized data showed no difference between the contraction count in the ICP curve measured at 10, 30, and 60 min after equilibrium (fig. 1E; P = 0.631, 0.642, and 0.913 in 10 vs. 30, 30 vs. 60, and 10 vs. 60 min, respectively, n = 7), indicating this modified balloon method reflects baseline colonic motility in routine circumstances.
Effects of Intrathecal Ghrelin
In experiments that tested the reliability of the modified balloon method in response to physiological challenges, cumulative administration of ghrelin (fig. 2A; 1, 3, and 10 μg/kg, 10 μl; intrathecal), but not of the vehicle solution (veh; 10 μl), enhanced colonic motility as characterized by provoking RCCs in the manometric tracing. Figure 2B shows that when compared with the preinjection control, spinal ghrelin administration at 1, 3, and 10 μg/kg increased the contraction count in the ICP curve in a dose-dependent manner (P = 0.021, P < 0.001, and P = 0.001 vs. control, respectively, n = 7), whereas no difference was found between the preinjection control and vehicle solution injections (P = 0.962 vs. control, n = 7). These results that imply the balloon technique used in this study responds to physiological impacts on colonic motility.
Effects of Intracolonic Acetic Acid
In contrast to the vehicle solution, which failed to affect colonic motility in the experiment testing the reliability of the modified balloon method in response to pathophysiological challenges (fig. 2C; veh, 0.2 ml), cumulative acetic acid injections (1, 3, and 10, 0.2 ml, intracolonic) enhanced colonic motility by provoking RCCs in the manometric tracing. The summarized data showed that when compared with the preinjection controls, intracolonic acetic acid injections increased the contraction count in the ICP curve in a dose-dependent manner (fig. 2D; P = 0.002, P < 0.001, and P < 0.001 vs. control in 1, 3, and 10, respectively, n = 7), suggesting this modified balloon technique responds to pathophysiological conditions.
MO-induced Uterus–Colon Cross-organ Sensitization
Next, colon manometry and the electromyogram activity of the rectus abdominis in response to uterine MO (0.1%, 0.2 ml) or CO (0.2 ml) injections were continuously recorded in anesthetized rats. We observed that in comparison with the preinjection control, CO injections into the uterine horn neither induced RCCs in the manometric recording nor triggered firing in the electromyogram tracing (fig. 3A). In contrast, MO administration (fig. 3B) dramatically provoked RCCs in the manometry and elicited synchronized burst electromyogram discharges. Figure 3, C and D, shows that uterine MO injections, but not CO injections, significantly increased the mean contraction count in the ICP curve (P = 0.002 and P = 0.778 vs. control, repectively, n = 7) and the mean area of integrated electromyogram (P = 0.003 and P = 0.716 vs. control, respectively, n = 7) compared with the preinjection control. These data imply that acute irritation of the uterus provokes colonic motility in a cross-organ manner.
MO-induced Spinal NR2B Phosphorylation
We next tested whether uterine MO administration could also induce spinal NMDAR NR2B subunit phosphorylation by using Western blot analysis of spinal dorsal horn samples (L6-S1) obtained at 10, 30, and 60 min after MO injections. We found that in correlation with the colonic hypermotility MO administration (0.1%, 0.2 ml) increased the band intensity labeled by the phosphorylated NR2B-specific antibody in a time-dependent manner (fig. 3E; pNR2B, normalized by the β-actin; P = 0.033, 0.008, and 0.002, vs. control in 10, 30, and 60 min, respectively, n = 7) when compared with the preinjection control. In contrast, this treatment failed to affect the band intensity labeled by the total NR2B-specific antibody at these time points (tNR2B; normalized by the β-actin; P = 0.864, 0.350, and 0.925 vs. control in 10, 30, and 60 min, respectively, n = 7), implying that spinal NR2B activation plays a key role in uterine–colon sensitization. We therefore focused our investigations on dorsal horn NR2B phosphorylation.
Uterus MO Instillation Induced No Colon Extravasation
We next tested whether acute intrauterine MO injections induce inflammation in the uterus or descending colon, by measuring the extravasation of Evans Blue dye in CO- or MO-treated animals. Figure 3F shows that in comparison to the preinjection control, it was MO (0.2 ml) but rather than CO (0.2 ml) administration into the uterine horn caused an increase in Evans Blue extravasation in the uterus extraction (P = 0.547 in CO and P = 0.001 in MO vs. control, both n = 7). In contrast, there was no difference found in the optical density of the colon extraction of CO- or MO-treated animals compared with the preinjection control (P = 0.578 in CO and P = 0.974 in MO vs. control, both n = 7), indicating that acute uterine MO injections provoke extravasation in the uterus itself rather than in the descending colon.
MO-induced NR2B Phosphorylation in Dorsal Horn Neurons
We used immunohistochemistry analysis to examine the cellular localization of the MO-induced NR2B phosphorylation. Staining of spinal cord sections (L6-S1; obtained 60 min after reagent instillation) for phosphorylated NR2B immunoreactivity demonstrated that in comparison with CO (fig. 4A), uterine administration of MO (fig. 4B) increased the immunoreactivity of phosphorylated NR2B in the dorsal horn. Moreover, double staining for phosphorylated NR2B and NeuN (neuron-specific nuclear protein, a neuronal marker), OX-42 (integrin αM, a microglial marker) or glial fibrillary acidic protein (an astrocyte marker) showed the MO-enhanced phosphorylated NR2B immunoreactivity overlapped with NeuN (fig. 4C) but not OX-42 (fig. 4D) or glial fibrillary acidic protein (fig. 4E), implying that the MO-enhanced NR2B phosphorylation occurs in dorsal horn neurons but not in glial cells.
MO Induced Uterus–Colon Crosstalk in a Dose-dependent Manner
Next, MO at concentrations of 0.05, 0.1, and 0.5% (fig. 5A; 0.2 ml) or CO (0.2 ml) was instilled into the uterine horn of urethane-anesthetized rats. In vivo manometric recordings demonstrated that CO instillation exhibited no effect whereas administration of MO induced colonic motility in a dose-dependent manner as evidenced by provoking RCCs when compared with the preinjection control. Figure 5B shows that MO administration at concentrations of 0.05, 0.1, and 0.5% increased the contraction count in the ICP curve in a dose-dependent manner when compared with the preinjection control (P = 0.009, 0.002, and 0.002, vs. control, respectively, n = 7).
Effects of Ro 25–6981 Pretreatment
We next used a selective antagonist to pharmacologically block spinal NR2B phosphorylation to further elucidate its role in the MO-induced uterus–colon crosstalk. As anticipated, uterine MO injections induced colonic motility (fig. 6, A and B; MO; 0.1%, 0.2 ml), as shown by significantly enhancing the contraction count in the ICP curve (fig. 6C; P < 0.001 and P = 0.001 vs. control in the left and right, respectively, n = 7) associated with an increase in the band intensity of the pNR2B in dorsal horn samples (fig. 6D; P < 0.001 vs. control, n = 7). The pretreated Ro 25–6981 (Ro + MO, an NR2B antagonist; 10 μM, 10 μl; intrathecal), unlike the vehicle solution (veh + MO, 10 μl, intrathecal), attenuated MO-induced hypermotility as shown by a significant decrease in the contraction count in the ICP curve compared with the MO-treated animals (fig. 6C; P = 0.007 in Ro + MO and P = 0.506 in veh + MO vs. MO, n = 7). Additionally, spinal Ro 25–6981 injections also prevented MO-induced dorsal horn NR2B phosphorylation because it significantly decreased the band intensity of pNR2B when compared with that in MO-treated animals (fig. 6D; P < 0.001 vs. MO, n = 7). Moreover, neither the contraction count in the ICP curve nor the intensity of the pNR2B band was affected by the injection of Ro 25–6981 during baseline control before MO instillation (data not shown). These results provide pharmacological support for the pivotal role of phosphorylation of spinal NR2B subunits in the uterus–colon crosstalk.
Effects of HC-030031 Pretreatment
As shown in figure 6B, uterine MO injections induced colon hypermotility by a significant increase in contraction count in the ICP curve (fig. 6C; P = 0.001 vs. control, n = 7) and an increase in the band intensity of pNR2B in the dorsal horn sample (fig. 6D). The administration of HC-030031 (30 mg/kg, 0.2 ml, HC + MO), but not the vehicle solution (veh + MO), into the uterine horn before MO injections attenuated MO-induced hypermotility (fig. 6B) as shown by a significant decrease in the contraction count in the ICP curve when compared with that in the MO-treated animals (fig. 6C; P = 0.002 in HC + MO and P = 0.924 in veh + MO vs. MO, n = 7). In addition, pretreatment with HC-030031 prevented MO-elicited spinal NR2B phosphorylation as demonstrated by a significant decrease in the intensity of the pNR2B band compared with the same in the MO-treated group (fig. 6D; P = 0.001 vs. MO, n = 7). Conversely, when HC-030031 was injected during baseline control before MO instillation, HC-030031 per se exhibited no effect on the contraction count in the manometric recording or in the level of dorsal horn pNR2B expression (data not shown). These results provide evidence that the activation of TRPA1 in the uterus could reflexively induce colon hypermotility via a mechanism involving the phosphorylation of the spinal NMDAR NR2B subunit.
Through a complex neural network innervating viscera,8,10,30 pathological alterations in one pelvic organ could lead to modifications in the function of others in a cross-organ manner.31–33 In the current study, acute MO dispensing into the uterus reflexively enhanced colonic motility by provoking RCCs. The possibility that MO directly established an organic injury in the descending colon and thereby resulted in colon hypermotility is unlikely because we administered MO into the lumen of the uterus rather than in the descending colon. This proposal is further supported by the fact that uterine MO administration led to Evans Blue extravasation in the uterus itself but not in the descending colon, indicating our procedure did not result in colon inflammation. That is, the enhanced colon motility demonstrated in this study is a phenomenon resembling functional bowel disorders, such as IBS, in which colon functions are altered without a known pathological etiology. Moreover, in accompanied with colon hypermotility, uterine MO injections provoked abdominal electromyogram discharges that were synchronized with the RCCs. Because it is well established that colon–rectal distension provokes visceromotor response characterized by enhanced electromyogram activity of abdominal striated muscle,17 abdominal electromyogram firing is used as an index of visceral pain, particularly in colon/rectum case. Our data suggest acute uterus irritation provokes colon hypermotility in a cross-organ manner; a phenomenon that could underlie the clinical finding that IBS, which is characterized by hyperactivity in the distal gastrointestinal tract in association with abdominal pain, often occurs in conjunction with obstetrical/gynecological inflammation.34–36
The understanding of the TRPA1 in pain-related behavior has advanced rapidly in recent years,18,19,37 and TRPA1 activation is currently recognized as necessary for the somatic pain provoked by intraplantar complete Freund adjuvant injection38 as well as the visceral pain caused by trinitrobenzene sulfonic acid- and dextran sulphate sodium–induced colitis.18,39 Although the therapeutic doses are still too high for drug development, known TRPA1 antagonist(s) play a promising role in vivo activity against cystitis-associated hyperalgesia,15 carrageenan-induced inflammatory pain,40 and postoperative guarding pain.41 By instilling a TRPA1 agonist, MO, into the lumen of uterine horn, we provoked cross-organ sensitization between the uterus and colon in this study. Conversely, pharmacological antagonism of uterine TRPA1 using HC-030031 abolished MO-induced uterus–colon crosstalk. Our result is the first demonstration that activation of uterine TRPA1 modified the function of pelvic viscera. This finding implies TRPA1 participates in the uterus physiology/pathophysiology and suggests that the development of pharmacological agents targeting TRPA1 is a possible therapeutic strategy for the treatment of pelvic visceral pain.
In the current study, we showed that activation of uterine TRPA1 induced colonic motility in a cross-organ manner. Considering that our previous investigation demonstrated that activation of uterus TRPV1 sensitized the urethra reflex activity,1 it would be interesting to test the likely interaction between these receptors because an electrophysiological study analyzed the TRPA1-mediated current in mouse trigeminal ganglion neurons and demonstrated synergic interactions between TRPA1 and TRPV1.42 Our unpublished data displayed that pretreated capsazepine, a selective TRPV1 antagonist, partially attenuated MO-induced uterus–colon crosstalk. However, whether this observation resulted from TRPA1–TRPV1 interactions or other mechanisms needs further study to be fully elucidated.
NR2B-containing NMDARs have been proposed to participate in the plasticity underlying hyperalgesia/allodynia43–49 because phosphorylation of NR2B tyrosine residues modulates NMDAR-mediated currents.50 In addition to its role in the development of spinal nerve ligation-induced neuropathic pain,48,51 the contribution of spinal NR2B to visceral pain was investigated in this study. Our results demonstrated that intrauterine MO instillation provoked colonic motility in association with NeuN- colocalized NR2B phosphorylation, both of which were thwarted by intrathecal dispensing of selective NR2B antagonist, Ro 25–6981. These findings suggest that activation of NR2B-containing NMDARs in dorsal horn neurons is crucially involved in the pain-related uterus–colon crosstalk. Though spinal NR2B subunits have been demonstrated to participate in the urethra3,20,21,52 and bladder hyperreflexia4 caused by acute colon irritation, our results are the first demonstration of a role of spinal NR2B in the cross-organ sensitization between the uterus and colon. With regard to a complex convergent neural network innervating and integrating the function of pelvic organs, including the urinary bladder, urethra, uterus, and colon,8,10,30 our findings suggest that spinal NR2B phosphorylation could be a common mechanism shared by the crosstalk between pelvic organs, in which irritation of one pelvic viscera induced spinal NR2B phosphorylation, thus provoking crosstalk with another viscera.
In the current study, a modified balloon manometric analysis was used to record colon motility. We observed that after an equilibrium period of stress-relaxation, a tracing with a relatively constant ICP was recorded before physiological/pathological manipulations, indicating this technique is a valid measurement of colonic motility under baseline physiological conditions. To test the reliability of this method in response to physiological and pathophysiological challenges, we intrathecally injected ghrelin and intracolonically infused acetic acid to the animal because in vivo studies have demonstrated that spinal ghrelin injection elicits propulsive colonic contractions27 and acute colonic irritation caused by acetic acid triggers colonic motility.23 Our results showed both these treatments provoked RCCs in a dose-dependent manner, indicating this modified manometry is a reliable measurement of motility changes in response to physiological and pathological perturbations. Although studies are needed to further verify the reliability and validity of the manometric analysis used in this study, this method provides an available technique for investigating colonic motility. Additionally, using this manometry technique, the design of this study offers an in vivo animal model to investigate the interaction between the colon and uterus, which elucidates the mechanism underlying the comorbidity of gynecological problems and IBS.
In summary, our findings not only established the feasibility of a unique model to study the impact of various treatments on colonic motility but also enabled an eventual characterization of the pathophysiological mechanisms involved in the development and comorbidity of uterus inflammation and IBS. Our data support the notion that the comorbidity of gynecological/obstetrical and gastrointestinal problems is not coincidental but rather causal in nature. Via the activation of uterine TRPA1, spinal NMDAR NR2B phosphorylation triggered by nociceptive afferents may set the foundation for the pathophysiological uterus–colon crosstalk. Perhaps leading to sensitization caused by the release of neurotrophic factors and other mediators,8 long-term or ongoing stimulation of these pathways may possibly lead to permanent sensory changes in the descending colon. Although further researches are warranted to expand on the current findings, we suggest that clinicians consider gynecological or urological disease in cases of bowel disease with no known pathological etiology.
This research was supported by grants from the National Science Council, Taipei, Taiwan (NSC 101-2320-B-715-001-MY3 and NSC 102-2628-B-715-001); Mackay Memorial Hospital, New Taipei, Taiwan (MMH-MM-10206; to Dr. Peng); Department of Health, Executive Yuan, Taipei, Taiwan (PG10107-0052; to Dr. Yeh); Mackay Memorial Hospital (MMH-10153); National Science Council (NSC 101-2314-B-195-002-MY2; to Dr. Cheng); and National Science Council (NSC 101-2320-B-039-013-MY3; to Dr. Lin).
The authors declare no competing interests.